Biocon Limited has announced comprehensive leadership changes following a Board meeting held on March 27, 2026. The pharmaceutical company is implementing a strategic transition that will see new appointments across key executive positions, effective April 1, 2026, as part of its integration with Biocon Biologics Limited.

Leadership Transition Details

The Board accepted resignations from two key executives effective March 31, 2026. Siddharth Mittal resigned from his position as Chief Executive Officer and Managing Director, while Mukesh Kamath stepped down as Interim Chief Financial Officer. Both executives will transition to other leadership roles within the Biocon Group.

New Executive Appointments

Shreehas Pradeep Tambe, currently serving as CEO and Managing Director of Biocon Biologics Limited, will assume the role of Chief Executive Officer and Managing Director of Biocon Limited. His appointment spans a five-year term beginning April 1, 2026, subject to shareholder approval. The Board also appointed him as an Additional Director effective the same date.

Kedar Narayan Upadhye, Chief Financial Officer of Biocon Biologics Limited, will become the new Chief Financial Officer of Biocon Limited. His appointment as Key Managerial Personnel and Senior Management Personnel takes effect April 1, 2026.

Strategic Vision and Leadership Statements

Kiran Mazumdar-Shaw, Executive Chairperson, emphasized the significance of this transition: "With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint."

Shreehas Tambe expressed his commitment to the new role: "It is an honor and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company. My focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth."

Executive Profiles and Background

Shreehas Tambe brings nearly three decades of experience at Biocon, having joined as a management trainee. Under his leadership as CEO & Managing Director of Biocon Biologics, the company achieved a valuation of USD 5.50 billion and became one of the world's Top 5 biosimilar companies by revenue. He holds a Master's degree in Bioprocess Technology from ICT, University of Mumbai, and is an inventor on 61 patents.

Kedar Narayan Upadhye joined Biocon Biologics as CFO and was instrumental in the company's USD 800.00 million bond issuance listed on the Singapore Exchange. He brings over 23 years of global leadership experience across corporate finance and strategy at leading companies including Cipla, Dr Reddy's Laboratories, and PepsiCo. He holds an MBA from IIM Bangalore and is a qualified Company Secretary and Cost Accountant.

Additional Key Personnel Changes

The Board designated Akhilesh Nand, Company Secretary of Biocon Biologics Limited, as Key Managerial Personnel and Senior Management Personnel. He will serve as Head, Governance, Risk and Compliance effective April 1, 2026.

Two new Senior Management Personnel appointments were approved:

Authorized Personnel for Regulatory Disclosures

The Board authorized five Key Managerial Personnel to determine materiality of events and make necessary disclosures to stock exchanges under Regulation 30 of SEBI Listing Regulations, effective April 1, 2026:

Strategic Context and Company Overview

These leadership changes align with Biocon's previously announced integration with Biocon Biologics Limited to create a unified global biopharmaceutical leader. The transition brings experienced executives from Biocon Biologics into key positions at the parent company, supporting the strategic consolidation of operations.

Biocon Limited operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. The company has commercialized 12 biosimilar products and 30+ generic formulations globally, with a robust research and development pipeline of 20+ biosimilar assets.

The Board meeting commenced at 10:50 A.M. and concluded at 11:35 A.M. on March 27, 2026. All appointments and changes comply with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Biocon Limited has announced a significant regulatory milestone with its wholly-owned subsidiary Biocon Pharma Limited receiving approval from the U.S. Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Liraglutide Injection. The company disclosed this development through a formal notification to stock exchanges.

Product Specifications and Indication

The approved ANDA covers Liraglutide Injection (gVictoza®) in a specific formulation designed for diabetes management. The product details are outlined below:

Liraglutide is specifically indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus, providing healthcare providers with another therapeutic option for managing this chronic condition across multiple age groups.

Strategic Portfolio Enhancement

This latest FDA approval represents the second Liraglutide-based product approval for Biocon in recent weeks. The company previously received approval for Liraglutide injection (gSaxenda®), demonstrating consistent regulatory success in this therapeutic area.

The dual approvals are expected to strengthen Biocon's portfolio of vertically integrated, complex drug products, positioning the company to better serve the diabetes treatment market in the United States. The complex nature of these injectable formulations aligns with Biocon's expertise in developing sophisticated pharmaceutical products and enhances its competitive positioning in the specialty therapeutics segment.

Regulatory Compliance and Disclosure

Biocon Limited fulfilled its regulatory disclosure obligations by notifying both major Indian stock exchanges about this development. The company submitted formal notifications to ensure transparency with stakeholders and compliance with listing requirements.

The notification was signed by the Company Secretary and Compliance Officer, and the information has been made available on the company's official website for broader stakeholder access.